Tranzyme Pharma (TZYM) and Ocera Therapeutics, Inc. Closing $20 Million PIPE Financing With Merger
4/24/2013 7:34:18 AM
More...
|
Ocera Therapeutics, Inc. Release: the Acute Liver Failure Study Group Initiates Phase 2a Study of OCR-002 for Treatment of Acute Liver Failure after Acetaminophen Overdose
11/8/2012 10:52:24 AM
More...
|
Preliminary Phase 2 Data of Ocera Therapeutics, Inc.' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction
5/29/2012 12:21:41 PM
More...
|
Ocera Therapeutics, Inc. Receives CE Mark for Zysa™ for the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-d)
5/18/2012 7:48:14 AM
More...
|
Ocera Therapeutics, Inc. Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy
12/15/2010 7:06:47 AM
More...
|
Data Presented by Ocera Therapeutics, Inc. at DDW Demonstrates that Neurocognitive Impairment is Highly Prevalent in Ambulatory Cirrhotic Patients
5/3/2010 10:57:26 AM
More...
|
Ocera Therapeutics, Inc. Demonstrates Proof of Principle for the Use of AST-120 in the Treatment of Non-Constipating Irritable Bowel Syndrome
5/3/2010 10:55:49 AM
More...
|
Ocera Therapeutics, Inc. Presents Data on the Prevalence of Mild Hepatic Encephalopathy Defined as Neurocognitive Impairment in Patients with Liver Cirrhosis at EASL Annual Meeting
4/16/2010 11:14:43 AM
More...
|
Ocera Therapeutics, Inc. Completes Phase 2B Enrollment in the ASTUTE Trial
2/24/2010 11:17:13 AM
More...
|
Ocera Therapeutics, Inc. Pursuing New Drug for Liver, Hopes to Help People Stay Mentally Sharp
11/25/2009 7:46:49 AM
More...
|
|